Vet

Cancer Does Not Have to Be a Death Sentence

Dr. Lucas Rodrigues

 

We are proud to share clinical relevant information from our peer-reviewed publication at NPJ Precision Oncology. Researchers at Stanford University and FidoCure have identified long survival times for dogs with cancer, even for aggressive types. 

Our peer-reviewed publication analyzed 2702 dogs with cancer. Tumor types were divided into 19 broad categories (in order of prevalence): hemangiosarcoma, transitional cell carcinoma, soft tissue sarcoma, osteosarcoma, mast cell tumor, melanoma, carcinoma (other), anal sac carcinoma, histiocytic sarcoma, pulmonary carcinoma, mammary carcinoma, undifferentiated carcinoma, undifferentiated sarcoma, lymphoma, squamous cell carcinoma, splenic carcinoma, thyroid carcinoma, GI carcinoma, nasal carcinoma, with the most common being hemangiosarcomas (~19%). Transitional cell carcinomas and soft tissue sarcomas are represented in ~15% and ~9% of dogs, respectively

MEDIAN SURVIVAL DAYS BY TUMOR TYPE 
Copy of OutcomesDataCompilation2023 (1)

As dedicated professionals, we understand the immense responsibility of guiding pet parents through the challenging decisions related to their dog's health, especially when facing cancer. The provision of precise information about the estimated survival time of dogs with cancer can profoundly impact the decisions pet parents make regarding treatment options. By presenting accurate prognostic data, we empower pet parents to make well-informed choices that align with their furry companion's best interests and overall quality of life. 

Clear and transparent communication about the potential outcomes allows them to weigh the benefits and potential challenges of treatment, ultimately fostering a strong sense of trust between pet parents and us as their veterinary partners.

Through our knowledge and support, we can help them navigate this difficult journey and ensure the most compassionate and appropriate care for their beloved canine friends.

We'd love to hear your thoughts on this data and how this can help your clinical decisions. Please comment below. 

DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy. 

© Copyright 2018-2022 OHC, All rights reserved